SALT LAKE CITY, Feb. 06, 2025 (GLOBE NEWSWIRE)
Myriad Genetics, Inc. & INTERLINK Care Management, Inc. Enhance Cancer Testing Access
Empowering CancerCARE for Life Members with Hereditary Cancer Testing
Myriad Genetics, Inc. and INTERLINK Care Management, Inc. have recently announced a groundbreaking agreement aimed at improving education and access to hereditary cancer testing for members of CancerCARE for Life. As leaders in genetic and genomic tumor testing and precision medicine, Myriad Genetics, Inc. (NASDAQ: MYGN) is renowned for its innovative approach to personalized healthcare. The collaboration with INTERLINK Care Management, Inc. will enable over one million individuals within CancerCARE’s network to determine their eligibility for the MyRisk test using the MyGeneHistory® quiz, a cutting-edge online patient screening tool based on clinical guidelines.
The MyRisk test provided by Myriad Genetics, Inc. is a comprehensive hereditary cancer panel that analyzes an individual’s genetic predisposition to various types of cancer. By leveraging the MyGeneHistory® quiz, CancerCARE for Life members can undergo a simple online assessment to evaluate their risk factors and potentially identify the need for further genetic testing. This proactive approach to cancer screening and prevention holds great promise for improving early detection and personalized treatment options for individuals at high risk of hereditary cancers.
By offering easy access to the MyRisk test through the MyGeneHistory® quiz, CancerCARE for Life is empowering its members to take control of their health and make informed decisions about their cancer risk. This partnership between Myriad Genetics, Inc. and INTERLINK Care Management, Inc. represents a significant advancement in the field of precision medicine, bridging the gap between genetic testing and patient care. Through education and accessibility, more individuals will have the opportunity to benefit from the latest advancements in cancer prevention and treatment.
As we look towards a future where personalized medicine plays an increasingly crucial role in healthcare, collaborations like the one between Myriad Genetics, Inc. and INTERLINK Care Management, Inc. are paving the way for more tailored and effective patient care. By leveraging genetic and genomic testing technologies, healthcare providers can identify at-risk individuals earlier, enabling proactive interventions that can ultimately save lives.
How Will This Impact Me?
For individuals like you, this agreement means greater access to advanced genetic testing for hereditary cancers. By taking the MyGeneHistory® quiz, you can assess your risk factors and determine if you may benefit from the MyRisk test. This proactive approach to cancer screening can provide valuable insights into your genetic predisposition to cancer and guide personalized treatment options for better health outcomes.
How Will This Impact the World?
On a global scale, initiatives like the collaboration between Myriad Genetics, Inc. and INTERLINK Care Management, Inc. have the potential to revolutionize cancer care. By expanding access to genetic testing and promoting early intervention strategies, this partnership is contributing to the advancement of precision medicine and the fight against hereditary cancers. The ripple effects of this collaboration may lead to improved healthcare outcomes for individuals worldwide, setting a new standard for personalized cancer prevention and treatment.
Conclusion
In conclusion, the agreement between Myriad Genetics, Inc. and INTERLINK Care Management, Inc. marks a significant milestone in the journey towards precision medicine and personalized cancer care. By empowering CancerCARE for Life members with access to the MyRisk test through the MyGeneHistory® quiz, this collaboration is poised to make a profound impact on individual health outcomes and global healthcare practices. As we continue to embrace innovative technologies and strategic partnerships in the field of genetic testing, the future of personalized medicine looks brighter than ever before.
